---
layout: default
title: Caplacizumab
description: "Caplacizumab 的老藥新用潛力分析。模型預測等級 L5，包含 10 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 僅模型預測 (L5)
nav_order: 38
evidence_level: L1
indication_count: 10
---

# Caplacizumab

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L5</strong> | 預測適應症: <strong>10</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Caplacizumab：從後天性TTP到血小板原發釋放障礙

## 一句話總結
<p class="key-answer" data-question="Caplacizumab 可以用於治療什麼新適應症？">
Caplacizumab 原為治療後天性血栓性血小板低下紫斑症(aTTP)的抗von Willebrand因子奈米抗體，TxGNN 預測其可能對血小板原發釋放障礙(primary release disorder of platelets)有治療潛力。
</p>


## 快速總覽
| 項目 | 內容 |
|------|------|
| 原適應症 | 後天性血栓性血小板低下紫斑症 (aTTP)，合併血漿置換術及免疫抑制劑使用 |
| 預測新適應症 | primary release disorder of platelets、pseudo-von Willebrand disease、Glanzmann thrombasthenia、Scott syndrome、thrombotic thrombocytopenic purpura、bleeding diathesis due to a collagen receptor defect、hemorrhagic disorder due to a constitutional thrombocytopenia、fetal and neonatal alloimmune thrombocytopenia、hemophilia、platelet-type bleeding disorder |
| TxGNN 預測分數 | 99.9998% |
| 證據等級 | L5 (僅預測) |
| 台灣上市 | 已上市 |
| 許可證數 | 1張 (多個包裝規格) |
| 建議決策 | Hold |




## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. primary release disorder of platelets</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">100.00%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>Caplacizumab 是一種人源化雙價奈米抗體(Nanobody)：</p>

<ol>
<li><strong>作用機轉</strong>：結合 von Willebrand 因子(vWF)的A1區域，阻斷血小板與vWF的交互作用</li>
<li><strong>抗血栓形成</strong>：防止血小板在vWF多聚體上的異常聚集</li>
<li><strong>高預測分數</strong>：TxGNN 給予極高分數(99.9998%)，排名第8</li>

</ol>
<p>然而，需謹慎看待此預測：</p>
<ul>
<li>血小板原發釋放障礙是血小板功能缺陷疾病，涉及血小板釋放反應異常</li>
<li>Caplacizumab 作用於 vWF-血小板軸，而非直接影響血小板釋放機制</li>
<li>理論上 caplacizumab 可能加重而非改善血小板功能障礙</li>
</ul>

<h3>臨床試驗</h3>

<p>目前無針對 caplacizumab 治療血小板原發釋放障礙的臨床試驗。</p>

<p><strong>與原適應症(aTTP)相關的重要臨床試驗</strong>：</p>

<ol>
<li><strong>HERCULES 試驗 (NCT02553317)</strong> - Phase III</li>
</ol>
<ul>
<li>145位患者參與</li>
<li>證實 caplacizumab 可顯著縮短血小板恢復時間</li>
<li>減少 aTTP 復發及相關死亡</li>

</ul>
<ol>
<li><strong>Post-HERCULES (NCT02878603)</strong> - 長期追蹤</li>
</ol>
<ul>
<li>評估 caplacizumab 的長期安全性</li>
<li>104位患者完成追蹤</li>

</ul>
<ol>
<li><strong>日本 Phase 2/3 試驗 (NCT04074187)</strong></li>
</ol>
<ul>
<li>21位日本患者</li>
<li>確認在亞洲族群的療效與安全性</li>
</ul>

<h3>相關文獻</h3>

<p>關於原適應症(aTTP)的重要文獻：</p>

<ol>
<li><strong>Scully M 等人 (2019)</strong> - *New England Journal of Medicine*</li>
</ol>
<ul>
<li>HERCULES 試驗結果發表</li>
<li>確立 caplacizumab 在 aTTP 治療中的地位</li>

</ul>
<ol>
<li><strong>Peyvandi F 等人 (2016)</strong> - *New England Journal of Medicine*</li>
</ol>
<ul>
<li>Phase II 試驗首次證實 caplacizumab 的療效</li>

</ul>
<ol>
<li><strong>Zheng XL 等人 (2020)</strong> - *Journal of Thrombosis and Haemostasis*</li>
</ol>
<ul>
<li>ISTH 治療 TTP 指引</li>
<li>納入 caplacizumab 作為標準治療選項</li>

</ul>
<p>無針對血小板原發釋放障礙的相關文獻。</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. pseudo-von Willebrand disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">100.00%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. Glanzmann thrombasthenia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">100.00%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. Scott syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">100.00%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. thrombotic thrombocytopenic purpura</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">100.00%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（14 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04720261" target="_blank">NCT04720261</a></td><td>PHASE2</td><td>UNKNOWN</td><td>125</td><td>Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monit...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06291025" target="_blank">NCT06291025</a></td><td>NA</td><td>NOT_YET_RECRUITING</td><td>131</td><td>Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Witho...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04985318" target="_blank">NCT04985318</a></td><td>N/A</td><td>RECRUITING</td><td>350</td><td>Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of Acq...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05785468" target="_blank">NCT05785468</a></td><td>N/A</td><td>UNKNOWN</td><td>1</td><td>A Retrospective, Observational Study on the Response to Caplacizumab Treatment i...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05468320" target="_blank">NCT05468320</a></td><td>PHASE3</td><td>COMPLETED</td><td>51</td><td>An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety...</td></tr>
</tbody>
</table>
<p><em>...及其他 9 項試驗</em></p>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30625070/" target="_blank">30625070</a></td><td>2019</td><td>Article</td><td>The New England jour</td><td>Caplacizumab Treatment for Acquired Thrombotic Thrombocytope...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28416507/" target="_blank">28416507</a></td><td>2017</td><td>Article</td><td>Blood</td><td>Thrombotic thrombocytopenic purpura.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26863353/" target="_blank">26863353</a></td><td>2016</td><td>Article</td><td>The New England jour</td><td>Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpur...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32914526/" target="_blank">32914526</a></td><td>2020</td><td>Article</td><td>Journal of thrombosi</td><td>ISTH guidelines for treatment of thrombotic thrombocytopenic...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32914582/" target="_blank">32914582</a></td><td>2020</td><td>Article</td><td>Journal of thrombosi</td><td>ISTH guidelines for the diagnosis of thrombotic thrombocytop...</td></tr>
</tbody>
</table>
<p><em>...及其他 15 篇文獻</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. bleeding diathesis due to a collagen receptor defect</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">100.00%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. hemorrhagic disorder due to a constitutional thrombocytopenia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">100.00%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. fetal and neonatal alloimmune thrombocytopenia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. hemophilia</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30625070/" target="_blank">30625070</a></td><td>2019</td><td>Article</td><td>The New England jour</td><td>Caplacizumab Treatment for Acquired Thrombotic Thrombocytope...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26863353/" target="_blank">26863353</a></td><td>2016</td><td>Article</td><td>The New England jour</td><td>Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpur...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32914526/" target="_blank">32914526</a></td><td>2020</td><td>Article</td><td>Journal of thrombosi</td><td>ISTH guidelines for treatment of thrombotic thrombocytopenic...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32914582/" target="_blank">32914582</a></td><td>2020</td><td>Article</td><td>Journal of thrombosi</td><td>ISTH guidelines for the diagnosis of thrombotic thrombocytop...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40235949/" target="_blank">40235949</a></td><td>2025</td><td>Article</td><td>EClinicalMedicine</td><td>Caplacizumab use in immune-mediated thrombotic thrombocytope...</td></tr>
</tbody>
</table>
<p><em>...及其他 15 篇文獻</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. platelet-type bleeding disorder</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（3 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05468320" target="_blank">NCT05468320</a></td><td>PHASE3</td><td>COMPLETED</td><td>51</td><td>An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07205861" target="_blank">NCT07205861</a></td><td>N/A</td><td>RECRUITING</td><td>1200</td><td>Auto-immune Thrombotic Thrombocytopenic Purpura : Retrospective Epidemiological ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06376786" target="_blank">NCT06376786</a></td><td>N/A</td><td>RECRUITING</td><td>132</td><td>Italian iTTP Registry (a Prospective Observational Study)</td></tr>
</tbody>
</table>

</div>
</details>


## 台灣上市資訊
| 許可證字號 | 商品名 | 劑型 | 許可證持有者 |
|-----------|--------|------|-------------|
| 衛部菌疫輸字第001243號 | 可利康凍晶注射劑10毫克 (Cablivi) | 注射劑 | 賽諾菲股份有限公司 |

核准適應症：
- 適用於合併血漿置換術及免疫抑制劑，治療後天性血栓性血小板低下紫斑症(aTTP)
- 適用族群：成人及12歲以上且體重40公斤以上的青少年

## 安全性考量
### 常見副作用
- 出血事件(鼻出血、牙齦出血最常見)
- 頭痛
- 蕁麻疹

### 嚴重警語
- 出血風險增加
- 使用期間應避免手術及侵入性處置
- 需監測出血徵象

### 藥物交互作用(主要)
| 交互作用藥物 | 嚴重程度 |
|-------------|---------|
| 阿斯匹靈 | 重度 |
| 抗凝血劑(apixaban, rivaroxaban等) | 重度 |
| 血小板抑制劑 | 重度 |
| Fondaparinux | 重度 |
| NSAIDs | 中度 |

## 結論與下一步
**證據等級**：L5 (僅 TxGNN 預測，無臨床或藥理學支持)

**建議**：Hold (暫不建議)
1. 血小板原發釋放障礙與 caplacizumab 的作用機轉無明顯關聯
2. 抑制 vWF-血小板交互作用理論上可能惡化而非改善血小板釋放功能
3. 極高的 TxGNN 分數可能反映兩者在血小板相關疾病知識圖譜中的位置接近，而非真正的治療關聯

**下一步建議**：
- 不建議進行臨床探索
- 若臨床遇到 aTTP 合併血小板功能障礙的病例，可收集相關數據以釐清
- 建議專注於 caplacizumab 在其他血栓性微血管病變(如非典型HUS)的潛在應用研究

**特別注意**：此預測可能為 TxGNN 演算法的偽陽性結果，臨床上不應依據此預測進行治療決策。


---

## 相關藥物報告

- [Potassium Iodide]({{ "/drugs/potassium_iodide/" | relative_url }}) - 證據等級 L5
- [Amorolfine]({{ "/drugs/amorolfine/" | relative_url }}) - 證據等級 L5
- [Clobetasone]({{ "/drugs/clobetasone/" | relative_url }}) - 證據等級 L5
- [Cerliponase Alfa]({{ "/drugs/cerliponase_alfa/" | relative_url }}) - 證據等級 L5
- [Travoprost]({{ "/drugs/travoprost/" | relative_url }}) - 證據等級 L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Caplacizumab老藥新用驗證報告. https://twtxgnn.yao.care/drugs/caplacizumab/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_caplacizumab,
  title = {Caplacizumab老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/caplacizumab/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
